Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 1;81(2):637-650.
doi: 10.1097/HEP.0000000000000584. Epub 2023 Aug 28.

HDV RNA assays: Performance characteristics, clinical utility, and challenges

Affiliations
Review

HDV RNA assays: Performance characteristics, clinical utility, and challenges

Heiner Wedemeyer et al. Hepatology. .

Erratum in

  • Erratum: HDV RNA assays: Performance characteristics, clinical utility, and challenges.
    Wedemeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor H, Kessler HH, Lenz O, Lütgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, Miller V, Terrault N, Lampertico P; HDV RNA Assays Writing Group at the HBV Forum. Wedemeyer H, et al. Hepatology. 2025 May 1;81(5):E149. doi: 10.1097/HEP.0000000000001262. Epub 2025 Mar 21. Hepatology. 2025. PMID: 40127116 Free PMC article. No abstract available.

Abstract

Coinfection with HBV and HDV results in hepatitis D, the most severe form of chronic viral hepatitis, frequently leading to liver decompensation and HCC. Pegylated interferon alpha, the only treatment option for chronic hepatitis D for many years, has limited efficacy. New treatments are in advanced clinical development, with one recent approval. Diagnosis and antiviral treatment response monitoring are based on detection and quantification of HDV RNA. However, the development of reliable HDV RNA assays is challenged by viral heterogeneity (at least 8 different genotypes and several subgenotypes), intrahost viral diversity, rapid viral evolution, and distinct secondary structure features of HDV RNA. Different RNA extraction methodologies, primer/probe design for nucleic acid tests, lack of automation, and overall dearth of standardization across testing laboratories contribute to substantial variability in performance characteristics of research-based and commercial HDV RNA assays. A World Health Organization (WHO) standard for HDV RNA, available for about 10 years, has been used by many laboratories to determine the limit of detection of their assays and facilitates comparisons of RNA levels across study centers. Here we review challenges for robust pan genotype HDV RNA quantification, discuss particular clinical needs and the importance of reliable HDV RNA quantification in the context of drug development and patient monitoring. We summarize distinct technical features and performance characteristics of available HDV RNA assays. Finally, we provide considerations for the use of HDV RNA assays in the context of drug development and patient monitoring.

PubMed Disclaimer

Conflict of interest statement

Heiner Wedemeyer consults, advises, is on the speakers’ bureau, and received grants from Gilead. He consults, advises, and is on the speakers’ bureau for Aligos Therapeutics, Altimmune, Bristol Myers Squibb, BTG, Dicerna, Enanta, Falk Foundation, Janssen, Merck KGaA, MYR GbmH, Roche, and Vir. He consults, advises, and received grants from AbbVie, Biotest AG. Thomas R. Battersby is employed by and owns stock in Gilead. He owns stock in Amgen and Roche. Jeffrey Glenn is employed by and owns stock in Eiger Biopharmaceuticals. Emmanuel Gordien consults and received grants from Eurobio and Gilead. Hema Kapoor is employed by and owns stock in Quest Diagnostics. She is employed by HK Healthcare Consultant. Oliver Lenz is employed by Janssen Pharmaceutica NV. He owns stock in Johnson & Johnson. Marc Lütgehetmann advises, is on the speakers’ bureau, and received grants from Roche. He is on the speakers’ bureau for Qiagen. Christian O. Simon is employed by and owns stock in Roche Diagnostics. Veronica Miller received grants from Abbott, Aligos Therapeutics, Altimmune, Antios Therapeutics, Assembly Biosciences, Eiger, Enyo Pharma, Gilead, GlaxoSmithKline, Hepatitis B Foundation, Immunocore, Janssen, Monogram Biosciences, Quest Diagnostics, RFS Family Foundation, Roche, VenatorX, Vir Biotechnology, Virion Therapeutics, and Viroclinics. Norah Terrault received grants from DSMB Moderna, Durect, Eiger, Gilead, GlaxoSmithKline, Helio Health, and Roche-Genentech. Pietro Lampertico advises and is on the speakers’ bureau for AbbVie, Aligos Therapeutics, Alnylam, Antios Therapeutics, Arrowhead, Bristol Myers Squibb, Eiger, Gilead, GlaxoSmithKline, Janssen, MSD, MYR, Roche, Spring Bank, and Vir. The remaining authors have no conflicts to report.

Figures

FIGURE 1
FIGURE 1
Worldwide distribution of HDV genotypes and subgenotypes. Countries harboring HDV-1 are in pale teal. HDV-1a and HDV-1b subgenotypes are localized to Africa and Madagascar, and HDV-1c to the Oceania islands, whereas HDV-1d is found in the Middle East, eastern and western Europe, Asia, and North America. HDV-2 (teal) is found in Asia, including in Taiwan and Japan for HDV-2a and Siberia for HDV-2b. HDV-3 (red) is present in the north of South America. HDV-4a and HDV-4b (light green) circulate in the Far East. HDV-5, HDV-6, HDV-7, and HDV-8 (dark green, orange, yellow, and blue, respectively) are present in western, sub-Saharan, and central Africa. Grey areas indicate regions where no data are yet available.

Similar articles

Cited by

References

    1. Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, Immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70:1782–94. - PMC - PubMed
    1. Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73:523–32. - PMC - PubMed
    1. Lampertico P, Roulot D, Wedemeyer H. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies. J Hepatol. 2022;77:1422–30. - PubMed
    1. Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): A multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2023;23:117–129. - PubMed
    1. Sandmann L, Wedemeyer H. New treatments for chronic hepatitis B virus/hepatitis D virus infection. Clin Liver Dis. 2021;25:831–9. - PubMed

MeSH terms